NYSE · LH
Healthcare · Medical - Equipment & Services
$320.71
Down-$2.02 (-0.63%)
Updated Sep 20, 2026, 4:53 PM
SID Score
7.0/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 19 trading sessions · Daily adjusted prices
LH closed at $320.71 after 19 trading sessions, down 5.49% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $322.00 | $322.70 | $319.38 | $320.71 | 1.74M |
| Sep 17, 2026 | $326.79 | $326.79 | $321.40 | $322.73 | 559.88K |
| Sep 16, 2026 | $323.51 | $325.30 | $320.38 | $324.51 | 561.4K |
| Sep 15, 2026 | $314.09 | $327.95 | $309.63 | $323.97 | 878.29K |
| Sep 14, 2026 | $314.12 | $316.485 | $308.21 | $315.31 | 707.84K |
| Sep 11, 2026 | $310.54 | $312.20 | $305.72 | $311.54 | 809.93K |
| Sep 10, 2026 | $320.58 | $320.62 | $305.45 | $306.96 | 1.26M |
| Sep 9, 2026 | $323.11 | $325.34 | $318.57 | $321.10 | 960.24K |
| Sep 8, 2026 | $321.18 | $328.065 | $318.67 | $324.86 | 615.72K |
| Sep 4, 2026 | $328.00 | $330.555 | $326.16 | $326.89 | 438.65K |
| Sep 3, 2026 | $333.47 | $335.74 | $329.38 | $331.50 | 520.65K |
| Sep 2, 2026 | $329.16 | $335.87 | $328.11 | $331.66 | 643.94K |
| Sep 1, 2026 | $335.27 | $336.65 | $326.51 | $327.61 | 571.75K |
| Aug 31, 2026 | $332.70 | $335.84 | $329.64 | $332.66 | 851.16K |
| Aug 28, 2026 | $336.39 | $337.69 | $334.42 | $335.11 | 456.55K |
| Aug 27, 2026 | $333.37 | $341.795 | $331.42 | $336.54 | 673.63K |
| Aug 26, 2026 | $335.83 | $339.40 | $334.41 | $335.72 | 701.21K |
| Aug 25, 2026 | $338.58 | $339.76 | $333.53 | $337.68 | 697.43K |
| Aug 24, 2026 | $335.99 | $339.76 | $334.40 | $339.34 | 466.31K |
The latest Smart Investors Daily articles mentioning LH.
LH research
Company profile and research snapshot.
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 11, 2026 | UBS | Buy | — |
| Sep 11, 2026 | Barclays | Equal-Weight | — |
| Aug 4, 2026 | Piper Sandler | Neutral | — |
| Aug 3, 2026 | JP Morgan | Overweight | — |
| Jul 31, 2026 | Truist Securities | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Sep 15, 2026
Labcorp Holdings Inc. (LH) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 11:30 AM EDTCompany ParticipantsAdam Schechter -...
Yahoo · Sep 14, 2026
Labcorp Holdings on Thursday presented a comprehensive growth strategy and long-term financial forecast during its 2026 Investor Day. The health care company emphasized its innovation roadmap, technological advancements and solid financial expectations for the coming years. Reaffirming Financial Targets The...
Yahoo · Sep 14, 2026
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.
SeekingAlpha · Sep 12, 2026
2026-09-12. The following slide deck was published by Labcorp Holdings Inc.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LH.
